Manufacturing

Articles

Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA. 

Samsung Biologics Incorporates Solentim’s Cell Line Development Technology into New R&D Center 

Mogrify’s new technology platform, EpiMOGRIFY, can predict cellular switches important for determining cell identity, cell maintenance, directed differentiation, and cell conversion.

New EpiMOGRIFY Technology Platform Offers Development Support for Allogeneic Cell Therapies

The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.

Samsung Biologics Expands Manufacturing Facilities and Launches Cell Line Technology

The candidates will be used by the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Dyadic International Selected for COVID-19 Vaccine Candidate Development

Catalent will use its GPEx cell line development technology to create a cell line expressing the recombinant VLP at its Madison, WI facility. 

Catalent Partners with Spicona for COVID-19 Vaccine Development

Solentim and ATUM will bundle together the Leap-In Transposase platform with the VIPS single cell cloning instrument for cell line development.

Solentim, ATUM Parnter on Cell Line Development

This milestone achievement will allow the companies to move forward with developing a GMP-compliant manufacturing process for clinical testing.

Immutep, Batavia Biosciences Generate High-Yielding LAG-3 Cell Line

Abcam has purchased Applied StemCell’s (ASC’s) gene editing platform and oncology product portfolio, adding comprehensive cell editing capabilities and engine to support expansion of existing “off-the-shelf” cell lines.


Abcam Purchases ASC’s Gene Editing Platform and Oncology Product Portfolio

The next-generation gene editing system can be applied to the development of novel cell and gene therapies.

Horizon Discovery Grants Access to Base Editing Technology

ProBioGen and Lava Therapeutics have closed the cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate.


Manufacturing, Cell-Line Selection